Logo image of NUWE

NUWELLIS INC (NUWE) Stock Fundamental Analysis

NASDAQ:NUWE - US67113Y7022 - Common Stock

4.89 USD
-0.04 (-0.71%)
Last: 9/4/2025, 8:25:51 PM
4.88 USD
-0.01 (-0.2%)
After Hours: 9/4/2025, 8:25:51 PM
Fundamental Rating

3

Taking everything into account, NUWE scores 3 out of 10 in our fundamental rating. NUWE was compared to 190 industry peers in the Health Care Equipment & Supplies industry. NUWE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NUWE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NUWE has reported negative net income.
NUWE had a negative operating cash flow in the past year.
In the past 5 years NUWE always reported negative net income.
NUWE had a negative operating cash flow in each of the past 5 years.
NUWE Yearly Net Income VS EBIT VS OCF VS FCFNUWE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of NUWE (-140.57%) is worse than 85.79% of its industry peers.
NUWE has a worse Return On Equity (-274.93%) than 76.32% of its industry peers.
Industry RankSector Rank
ROA -140.57%
ROE -274.93%
ROIC N/A
ROA(3y)-132.73%
ROA(5y)-110.12%
ROE(3y)-328.31%
ROE(5y)-233.66%
ROIC(3y)N/A
ROIC(5y)N/A
NUWE Yearly ROA, ROE, ROICNUWE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

The Gross Margin of NUWE (63.18%) is better than 64.74% of its industry peers.
NUWE's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NUWE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.63%
GM growth 5Y4.66%
NUWE Yearly Profit, Operating, Gross MarginsNUWE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

NUWE does not have a ROIC to compare to the WACC, probably because it is not profitable.
NUWE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NUWE has more shares outstanding
There is no outstanding debt for NUWE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NUWE Yearly Shares OutstandingNUWE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
NUWE Yearly Total Debt VS Total AssetsNUWE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -62.09, we must say that NUWE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NUWE (-62.09) is worse than 94.74% of its industry peers.
NUWE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -62.09
ROIC/WACCN/A
WACC8.86%
NUWE Yearly LT Debt VS Equity VS FCFNUWE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

NUWE has a Current Ratio of 2.23. This indicates that NUWE is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.23, NUWE perfoms like the industry average, outperforming 41.58% of the companies in the same industry.
NUWE has a Quick Ratio of 1.59. This is a normal value and indicates that NUWE is financially healthy and should not expect problems in meeting its short term obligations.
NUWE has a Quick ratio of 1.59. This is comparable to the rest of the industry: NUWE outperforms 44.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 1.59
NUWE Yearly Current Assets VS Current LiabilitesNUWE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

NUWE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.69%, which is quite impressive.
Looking at the last year, NUWE shows a decrease in Revenue. The Revenue has decreased by -1.25% in the last year.
NUWE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.67% yearly.
EPS 1Y (TTM)71.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38%
Revenue 1Y (TTM)-1.25%
Revenue growth 3Y3.34%
Revenue growth 5Y9.67%
Sales Q2Q%2.53%

3.2 Future

Based on estimates for the next years, NUWE will show a very strong growth in Earnings Per Share. The EPS will grow by 25.97% on average per year.
NUWE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.06% yearly.
EPS Next Y97.08%
EPS Next 2Y40.93%
EPS Next 3Y25.97%
EPS Next 5YN/A
Revenue Next Year2.8%
Revenue Next 2Y24.85%
Revenue Next 3Y35.82%
Revenue Next 5Y45.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NUWE Yearly Revenue VS EstimatesNUWE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
NUWE Yearly EPS VS EstimatesNUWE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -200M -400M -600M -800M -1B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NUWE. In the last year negative earnings were reported.
Also next year NUWE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUWE Price Earnings VS Forward Price EarningsNUWE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUWE Per share dataNUWE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

NUWE's earnings are expected to grow with 25.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.93%
EPS Next 3Y25.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NUWE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUWELLIS INC

NASDAQ:NUWE (9/4/2025, 8:25:51 PM)

After market: 4.88 -0.01 (-0.2%)

4.89

-0.04 (-0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners1.28%
Inst Owner Change144.34%
Ins Owners0.02%
Ins Owner Change99.63%
Market Cap4.40M
Analysts82.86
Price TargetN/A
Short Float %2.93%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.3%
Min EPS beat(2)-59.6%
Max EPS beat(2)10.99%
EPS beat(4)2
Avg EPS beat(4)15.13%
Min EPS beat(4)-124.14%
Max EPS beat(4)233.27%
EPS beat(8)5
Avg EPS beat(8)18.63%
EPS beat(12)7
Avg EPS beat(12)13.66%
EPS beat(16)10
Avg EPS beat(16)12.63%
Revenue beat(2)0
Avg Revenue beat(2)-12.68%
Min Revenue beat(2)-17.82%
Max Revenue beat(2)-7.53%
Revenue beat(4)1
Avg Revenue beat(4)-4.89%
Min Revenue beat(4)-17.82%
Max Revenue beat(4)7.39%
Revenue beat(8)2
Avg Revenue beat(8)-4.25%
Revenue beat(12)4
Avg Revenue beat(12)-5.2%
Revenue beat(16)6
Avg Revenue beat(16)-5.08%
PT rev (1m)0%
PT rev (3m)-15.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25%
EPS NY rev (1m)0%
EPS NY rev (3m)6.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.5
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-75.49
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-10.33
FCFYN/A
OCF(TTM)-10.29
OCFYN/A
SpS9.76
BVpS3.98
TBVpS3.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -140.57%
ROE -274.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.18%
FCFM N/A
ROA(3y)-132.73%
ROA(5y)-110.12%
ROE(3y)-328.31%
ROE(5y)-233.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.63%
GM growth 5Y4.66%
F-Score5
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.1%
Cap/Sales 0.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 1.59
Altman-Z -62.09
F-Score5
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)40.1%
Cap/Depr(5y)48.83%
Cap/Sales(3y)1.63%
Cap/Sales(5y)2.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38%
EPS Next Y97.08%
EPS Next 2Y40.93%
EPS Next 3Y25.97%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.25%
Revenue growth 3Y3.34%
Revenue growth 5Y9.67%
Sales Q2Q%2.53%
Revenue Next Year2.8%
Revenue Next 2Y24.85%
Revenue Next 3Y35.82%
Revenue Next 5Y45.06%
EBIT growth 1Y43.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.61%
OCF growth 3YN/A
OCF growth 5YN/A